Notice of Interim Results

RNS Number : 0596Z
Futura Medical PLC
29 August 2018
 

 

Notice of Interim Results

29 August 2018

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will announce its interim results for the six months ended 30 June 2018 and provide a trading update on Wednesday 26 September 2018.

James Barder, Chief Executive Officer, and Angela Hildreth, Finance Director/Chief Operating Officer, will host a presentation for analysts at 10am BST on the day of the results at Devonshire Club, 5 Devonshire Square, London, EC2M 4YD.

There will be a live webcast of the analyst presentation. If you would like to listen to the webcast, please log on to the following web address approximately 5 minutes before 10am BST on the day of results: https://www.futuramedical.com/content/financial/annual_reports.asp

A recording of the webcast will also be made available following the results meeting.

To register attendance at the meeting, please contact Optimum Strategic Communications for further details.

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Tel: +44 (0) 1483 685 670
 

Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow
Tel: +44 (0) 20 7496 3000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 714 1787

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORSEWFAAFASEFA
UK 100

Latest directors dealings